CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Company Overview - CG Oncology, Inc. (CGON) is expected to report flat earnings compared to the previous year, with a projected quarterly loss of $0.36 per share, indicating no change from the year-ago quarter [3][10] - Revenues are anticipated to be $0.6 million, reflecting a 13.2% increase from the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4] - The Zacks Earnings ESP for CG Oncology is -21.30%, suggesting a bearish sentiment among analysts regarding the company's earnings prospects [10][11] Historical Performance - In the last reported quarter, CG Oncology was expected to post a loss of $0.41 per share but actually reported a loss of $0.48, resulting in a surprise of -17.07% [12] - Over the past four quarters, the company has beaten consensus EPS estimates two times [13] Comparison with Industry Peers - Stoke Therapeutics, Inc. (STOK), another player in the Zacks Medical - Biomedical and Genetics industry, is expected to post a loss of $0.37 per share, which represents a year-over-year change of +35.1% [17] - Stoke Therapeutics has an Earnings ESP of 32.43% and a Zacks Rank of 2 (Buy), indicating a higher likelihood of beating the consensus EPS estimate [18]